Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The MicroRNA-200 (miR-200) family is a group of five highly conserved microRNAs (miR-200a, miR-200b, miR-200c, miR-141, and miR-429) that are essential regulators of the epithelial phenotype (Gregory et al., 2008). They function primarily by suppressing the expression of the E-cadherin transcriptional repressors ZEB1 and ZEB2, thereby inhibiting the epithelial-mesenchymal transition (EMT), a process critical for cancer metastasis and fibrosis (Park et al., 2008; Korpal et al., 2008). In many epithelial-derived cancers, the miR-200 family is frequently downregulated, which correlates with increased invasiveness and resistance to conventional therapies (Brabletz & Brabletz, 2010). Conversely, their expression is sometimes upregulated during the mesenchymal-epithelial transition (MET) required for metastatic colonization in distant organs. Therapeutic approaches involve the use of synthetic miR-200 mimics to restore tumor-suppressive functions or antagomirs to block their activity in specific pathological contexts. Despite their therapeutic potential, challenges remain regarding the precise delivery of these RNA-based molecules to target tissues and the avoidance of off-target effects (Humphries & Yang, 2015).
Post-transcriptional gene silencing via binding to the 3' untranslated region (UTR) of target mRNAs, particularly ZEB1 and ZEB2, to inhibit translation or induce mRNA degradation.
1 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on MicroRNA-200 family (miR-200 family).